EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Tislelizumab-induced hyperosmolar diabetic ketoacidosis complicated with rhabdomyolysis in hepatocellular carcinoma patients: case report

Longjun Chen, Xiaojuan Zeng, Tianping Li

Frontiers in Oncology · 10.04.2026 · 16

DOI: 10.3389/fonc.2026.1806333 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 10.04.2026. Verfasst von Longjun Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, West China Hospital, West China Xiamen Hospital, Sichuan University, Xiamen, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tislelizumab has been approved for the treatment of various solid tumors. While using it for treatment, it is crucial to pay attention to immune-related adverse events (irAEs), as these often have irreversible consequences for patients. We report a case of a 74-year-old male patient with hepatocellular carcinoma who developed ICI-induced diabetes after receiving tislelizumab treatment. The patient presented with altered mental status, and examination revealed hyperglycemia. He had no prior history of diabetes. Based on laboratory results, he was diagnosed with tislelizumab-induced hyperosmolar diabetic ketoacidosis complicated with rhabdomyolysis. Currently, there are few reported cases of hyperosmolar diabetic ketoacidosis(H-DKA) complicated with rhabdomyolysis caused by immune checkpoint inhibitors, this article aims to clarify the differences in clinical presentation among patients with concurrent rhabdomyolysis and to emphasize the importance for clinicians to identify such immune-related adverse events in patients receiving ICI treatment.

Schlagwörter

Stichwörter der Autor:innen

PD-1 inhibitorshyperosmolar diabetic ketoacidosis (H-DKA)immune checkpoint inhibitorsimmune-related adverse eventrhabdomyolysistislelizumab

Autor:innen und Institutionen

  • Department of Pharmacy, West China Hospital, West China Xiamen Hospital, Sichuan University, Xiamen, China.
  • Pediatrics, The Second Hospital of Zhangzhou, Zhangzhou, China.
  • Department of Pharmacy, West China Hospital of Sichuan University, Sichuan, Chengdu, China.

Zitieren

APA

Chen, L., Zeng, X., & Li, T. (2026). Tislelizumab-induced hyperosmolar diabetic ketoacidosis complicated with rhabdomyolysis in hepatocellular carcinoma patients: case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1806333

Vancouver

Chen L, Zeng X, Li T. Tislelizumab-induced hyperosmolar diabetic ketoacidosis complicated with rhabdomyolysis in hepatocellular carcinoma patients: case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1806333

BibTeX
@article{Chen2026,
  author = {Chen, Longjun and Zeng, Xiaojuan and Li, Tianping},
  title = {Tislelizumab-induced hyperosmolar diabetic ketoacidosis complicated with rhabdomyolysis in hepatocellular carcinoma patients: case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1806333}
}
Kostenlos starten →